

C T F A

THE COSMETIC, TOILETRY, AND FRAGRANCE ASSOCIATION

TALC INTERESTED PARTIES

E. EDWARD KAVANAUGH
P R E S I D E N T

AGENDA

CTFA
Main Conference Room
1101 17th Street, N.W., Suite 300
Washington, DC 20036

January 11, 1994
10:00 AM - 3:00 PM

- I. OPENING REMARKS**
- II. UPDATE ON FDA/IS RTP SYMPOSIUM**
- III. OVARIAN CANCER**
 - Recent Publications
 - Meta-Analysis Manuscript Review
- IV. ATTENDANCE AT THE SYMPOSIUM**
 - Consultants
 - Response to Questions
- V. PREPARATION OF PRESS RESPONSE STATEMENT**
- VI. NEXT STEPS/NEXT MEETING**
- VII. ADJOURNMENT**

H:\sdg\talc\agendas.94-1

1101 17TH ST., N.W., SUITE 300 WASHINGTON, D.C. 20036-4702
202.331.1770 FAX 202.331.1969
SECURING THE INDUSTRY'S FUTURE SINCE 1894

AV_RODRIGUEZN-0000257

Fixed
8/5/93

AGREEMENT:

PARTICIPATION IN CTFA TALC
INTERESTED PARTY TASK FORCE SPONSORSHIP
OF FDA/IS RTP WORKSHOP ON TALC SAFETY

On behalf of Avon Products, Inc. we agree to commit to provide
funding (Company)

up to a maximum of \$ 2,000.00 to participate in the CTFA Talc Interested Party
Task Force sponsorship of the FDA/IS RTP Workshop on talc safety.

We understand that an additional 10% per year of all direct costs incurred by CTFA in support
of the Workshop (excluding CTFA staff salaries and benefits, and to a maximum of \$10,000 in any
calendar year) will be charged back to the Interested Parties for administrative overhead.

We further understand that as a member of the Talc Interested Party Task Force we will have
equal access to all reports generated by and for CTFA in conjunction with the Workshop. We also
understand that such reports will become public documents upon finalization by the Task Force.

Kevin J. Randle
(Signature)

8/5/93
(Date)

Manager, Toxicology
(Title)

Please send your response by facsimile, immediately, to: Ms. Pandora Dennis, CTFA,
(202) 331-1969

sdg\Talc\agreement

TALC INTERESTED PARTIES

AGENDA

CTFA
Main Conference Room
1101 17th Street, N.W., Suite 300
Washington, DC 20036

January 11, 1994
10:00 AM - 3:00 PM

- I. OPENING REMARKS
- II. UPDATE ON FDA/IS RTP SYMPOSIUM
- III. OVARIAN CANCER
 - Recent Publications
 - Meta-Analysis Manuscript Review
- IV. ATTENDANCE AT THE SYMPOSIUM
 - Consultants
 - Response to Questions
- V. PREPARATION OF PRESS RESPONSE STATEMENT
- VI. NEXT STEPS/NEXT MEETING
- VII. ADJOURNMENT